首页> 外文期刊>Der Pharma Chemica: journal for medicinal chemistry, pharmaceutical chemistry and computational chemistry >Insilico designing and development of potent drug inhibitor to MDM2 protein in cancer through molecular docking studies
【24h】

Insilico designing and development of potent drug inhibitor to MDM2 protein in cancer through molecular docking studies

机译:通过分子对接研究,Silical设计和开发针对癌症的MDM2蛋白有效药物抑制剂

获取原文
           

摘要

Cancer is a class of diseases characterized by out-of-control cell growth. Cancer is a leading cause of death worldwide.The p53 tumor suppressor is one of the principal mediators of cell-cycle arrest and the activation of apoptosis in response to cellular injuries . In normal unstressed cells, p53 is regulated by a feedback loop with the negative regulator protein MDM2 (murine double -minute clone 2, referred to as human double –minute clone 2, HDM2 , in humans) . A well -known mechanism for the loss of wild –type p53 activity in cancer cells is the overexpression of MDM2.The murine double minute 2 (MDM2) protein facilitates G1 to S phase transition by activation of E2F-1 and can enhance cell survival by suppressing wild-type p53 function.Murine DM2 (MDM2) protein is overexpressed in a variety of neoplasms, including acute leukemias, myelodysplastic syndrome, chronic lymphocytic leukemia and lymphomas , multiple myelomas etc. Blocking the MDM2-p53 interaction to reactivate the p53 function is a promising cancer therapeutic strategy. Activation of the p53 protein protects the organism against the propagation of cells that carry damaged DNA with potentially oncogenic mutations. This can be attained by designing a molecule which can bind to P53 transactivation site of Mdm2 and further this Mdm2 protein cannot bind with P53 .The aim of present study is designing a small molecule(antagonist) having capability to bind with the over expressed Mdm2 protein and blocking its path to bind with p53 tumour suppressor protein that is having sufficient absorption and free of hepatotoxicity and carcinogenicity.
机译:癌症是一类以细胞生长失控为特征的疾病。癌症是世界范围内主要的死亡原因。p53抑癌剂是细胞周期停滞和细胞凋亡响应细胞损伤的主要介体之一。在正常的无应激细胞中,p53受负调节蛋白MDM2(鼠双性克隆2,在人中称为人双性克隆2,HDM2)的反馈环调节。癌细胞中野生型p53活性丧失的一种众所周知的机制是MDM2的过表达。鼠类双分钟2(MDM2)蛋白通过激活E2F-1促进G1到S期的转变,并通过增加E2F-1的存活率来提高其存活率。鼠DM2(MDM2)蛋白在多种肿瘤中过度表达,包括急性白血病,骨髓增生异常综合症,慢性淋巴细胞白血病和淋巴瘤,多发性骨髓瘤等。阻断MDM2-p53相互作用以重新激活p53功能是一种有前途的癌症治疗策略。 p53蛋白的激活可以保护生物体,使其免受携带带有潜在致癌突变的受损DNA的细胞的繁殖。这可以通过设计一种可以与Mdm2的P53反式激活位点结合的分子来实现,而且该Mdm2蛋白不能与P53结合。本研究的目的是设计一种具有与过量表达的Mdm2蛋白结合的能力的小分子(拮抗剂)。并阻断其与具有充分吸收并且无肝毒性和致癌性的p53肿瘤抑制蛋白结合的途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号